Normal P50 Suppression in Schizophrenia Patients Treated With Atypical Antipsychotic Medications
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Patients with schizophrenia have deficits in attention, cognition, and information processing. Measures such as P50 suppression are used to study cognitive and attentional dysfunction among these patients. P50 suppression is an operational measure of sensory gating that can be assessed by averaging electroencephalographic responses to multiple pairs of auditory clicks separated by 500 msec. Normally, the P50 response to the second click is smaller than the response to the first click. Many studies have demonstrated that schizophrenia patients have deficient P50 suppression, meaning that the difference between the first and second clicks is not as large as normal. Atypical antipsychotic medications may have superior clinical efficacy for negative symptoms and cognitive deficits. It is important, therefore, to evaluate the effects of atypical antipsychotic medications on measures such as P50 suppression. METHOD: P50 suppression of 13 patients with schizophrenia receiving clinically effective doses of clozapine, olanzapine, or risperidone (classified as atypical antipsychotic medications) was compared to that of 13 patients receiving conventional antipsychotic medications. RESULTS: The patient groups did not differ on clinical or demographic measures. The patients receiving atypical antipsychotic medications had normal-range P50 suppression (mean=72%). In contrast, the patients receiving typical antipsychotic medications had dramatically lower P50 suppression (mean=27%). CONCLUSIONS: The results support the hypothesis that patients treated with atypical antipsychotic medications have normal P50 measures of sensory gating. Longitudinal within-subjects studies are warranted to clarify the mechanisms mediating this effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cohen, J. (1994) · American Psychologist · doi:10.1037/0003-066x.49.12.997 · Cited by 4,003
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141
Cited by
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Turetsky, B. I., Calkins, M. E., Light, G. A., Olincy, A., Radant, A. D., & Swerdlow, N. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl060 · Cited by 567
Self-citationBraff, D. L., Freedman, R., Schork, N. J., & Gottesman, I. I. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl049 · Cited by 455
Self-citationGreenwood, T. A., Braff, D. L., Light, G. A., Cadenhead, K. S., Calkins, M. E., Dobie, D. J., Freedman, R., Green, M. F., Gur, R. E., Gur, R. C., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.11.1242 · Cited by 381
Self-citationAddressing tobacco among individuals with a mental illness or an addiction
Williams, J. M., & Ziedonis, D. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.03.009 · Cited by 359
P50 sensory gating ratios in schizophrenics and controls: A review and data analysis
Patterson, J. V., Hetrick, W. P., Boutros, N. N., Jin, Y., Sandman, C., Stern, H., Potkin, S., & Bunney, W. E. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.02.009 · Cited by 352
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia
Martin, L., Kem, W., & Freedman, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1750-1 · Cited by 342
Neurophysiological biomarkers for drug development in schizophrenia
Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G., & Hajós, M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2463 · Cited by 342
Neuronal substrates of sensory gating within the human brain
Grunwald, T., Boutros, N. N., Pezer, N., von Oertzen, J., Fernández, G., Schaller, C., & Elger, C. E. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01673-6 · Cited by 316
Evidence for Impaired Cortical Inhibition in Schizophrenia Using Transcranial Magnetic Stimulation
Daskalakis, Z. J., Christensen, B. K., Chen, R., Fitzgerald, P. B., Zipursky, R. B., & Kapur, S. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.4.347 · Cited by 301
Review of Clinical Correlates of P50 Sensory Gating Abnormalities in Patients with Schizophrenia
Potter, D., Summerfelt, A., Gold, J., & Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj050 · Cited by 259
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Neuromodulation in Tourette syndrome: dopamine and beyond
Buse, J., Schoenefeld, K., Münchau, A., & Roessner, V. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.10.004 · Cited by 185
Generators of the intracranial P50 response in auditory sensory gating
Korzyukov, O., Pflieger, M. E., Wagner, M., Bowyer, S. M., Rosburg, T., Sundaresan, K., Elger, C. E., & Boutros, N. N. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.12.011 · Cited by 183
“, 2004; Heinrichs, 2004), the effect of medications (Freedman et al., 1983; Light et al., 2000; Nagamoto et al., 1996), and the genetic factors (Freedman et al.”
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate
Hong, L. E., Summerfelt, A., Mitchell, B. D., McMahon, R. P., Wonodi, I., Buchanan, R. W., & Thaker, G. K. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.9.1008 · Cited by 115
The role of cortical inhibition in the pathophysiology and treatment of schizophrenia
Daskalakis, Z. J., Fitzgerald, P. B., & Christensen, B. K. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.006 · Cited by 111
Braff, D. L., Light, G. A., & Swerdlow, N. R. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.015 · Cited by 90
Self-citationDistinct neural generators of sensory gating in schizophrenia
Williams, T. J., Nuechterlein, K. H., Subotnik, K. L., & Yee, C. M. (2011) · Psychophysiology · doi:10.1111/j.1469-8986.2010.01119.x · Cited by 67
Measuring P50 suppression and prepulse inhibition in a single recording session
Light, G. A., & Braff, D. L. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2066 · Cited by 59
Self-citationKéri, S., Beniczky, S., & Kelemen, O. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09050723 · Cited by 35
Smucny, J., Stevens, K. E., Olincy, A., & Tregellas, J. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.77 · Cited by 28
Increasing Dopaminergic Activity: Effects of L-Dopa and Bromocriptine on Human Sensory Gating
Oranje, B., Gispen-de Wied, C. C., Westenberg, H. G. M., Kemner, C., Verbaten, M. N., & Kahn, R. S. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800310 · Cited by 27
Whitton, A. E., Lewandowski, K. E., & Hall, M.-H. (2021) · Brain Sciences · doi:10.3390/brainsci11121581 · Cited by 4
“For example, it has been reported that impaired sensory gating is associated with greater difficulties in attention, poorer working memory, or reduced processing speed [25–28], although other studies fail to find evidence of these associations [29].”
Background
Metadata
- Authors
- Light, G. A., Geyer, M. A., Clementz, B. A., Cadenhead, K. S., & Braff, D. L.
- Venue
- American Journal of Psychiatry
- Published
- 2000-05-01
- Volume
- 157
- Issue
- 5
- Pages
- 767-771
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2165525034
- Cited by
- 206
- References
- 2
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.